Correction of metabolic disorders in patients co-infected with HIV/HCV

Abstract

There was studied an effectiveness of phosphogliv in correction of metabolic disorders in patients co-infected with HIV\HCV.Methods: There were examined 40 patients co-infected with HIV|HCV separated into two groups. 1 group included 22 patients co-infected with HIV\HCV who received phosphogliv, 2 capsules 3 times a day during 6 month. The second group included 18 patients who received simvastatin, 10mg\kg\day during 6 month.Results: Phosphogliv therapy leads to reliable decrease of ІL-8, ІL-10, ІL-1β, ІL-6, TNF-α and increase of ІL-2. In patients of the 1 group it were registered the reliable decrease of potassium and also increase of sodium, calcium, magnesium, zinc, copper and iron after treatment. Under an influence of phosphogliv it was observed reliable decrease of the level of insulin resistance, glycated hemoglobin, insulin, glucose and uric acid.Phosphogliv favors reliably more intense influence on cytokine (р<0,05), mineral (р<0,001) and carbohydrate metabolism (р<0,05) compared to simvastatin. Both preparations favor an intense positive dynamics of the lipid spectrum parameters but in patients who received simvastamin it was registered the more significant increase of HDL and therapy with phosphogliv leads to reliably more significant decrease of LDL (р<0,05) and VLDL(р<0,01).Conclusions: Phosphogliv is very effective in correction of metabolic disorders in patients co-infected with HIV\HCV it favors the reliable positive dynamics of parameters of cytokine, mineral, lipid and carbohydrate types of metabolism. Phosphogliv has the more intense effect on cytokine, mineral and carbohydrate metabolism compared to simvastatin